Wall Street Zen lowered shares of Kestra Medical Technologies (NASDAQ:KMTS – Free Report) from a hold rating to a sell rating in a research report report published on Saturday,Wall Street Zen reports.
A number of other brokerages have also weighed in on KMTS. Oppenheimer assumed coverage on Kestra Medical Technologies in a research report on Tuesday, July 21st. They set a “market perform” rating on the stock. BTIG Research reaffirmed a “buy” rating and issued a $32.00 price objective on shares of Kestra Medical Technologies in a research note on Wednesday, September 2nd. Wolfe Research set a $30.00 price objective on shares of Kestra Medical Technologies in a report on Wednesday, July 15th. JPMorgan Chase & Co. started coverage on shares of Kestra Medical Technologies in a research report on Monday, August 10th. They set an “overweight” rating and a $30.00 target price for the company. Finally, Weiss Ratings lowered shares of Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, August 31st. Four equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $28.14.
View Our Latest Stock Report on Kestra Medical Technologies
Kestra Medical Technologies Stock Performance
Kestra Medical Technologies (NASDAQ:KMTS – Get Free Report) last announced its quarterly earnings results on Monday, September 14th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.61) by ($0.14). Kestra Medical Technologies had a negative return on equity of 57.38% and a negative net margin of 138.35%.The firm had revenue of $30.97 million during the quarter. On average, research analysts anticipate that Kestra Medical Technologies will post -2.29 earnings per share for the current fiscal year.
Insider Transactions at Kestra Medical Technologies
In other news, Director Mary Ladone sold 3,908 shares of the stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $25.20, for a total value of $98,481.60. Following the completion of the sale, the director owned 37,507 shares in the company, valued at $945,176.40. This represents a 9.44% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Jeffrey Schwartz sold 3,890 shares of the company’s stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $25.18, for a total transaction of $97,950.20. Following the completion of the sale, the director directly owned 7,019 shares of the company’s stock, valued at $176,738.42. The trade was a 35.66% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders have sold 239,588 shares of company stock worth $5,802,688. 5.30% of the stock is owned by insiders.
Institutional Trading of Kestra Medical Technologies
Institutional investors and hedge funds have recently modified their holdings of the business. Quantinno Capital Management LP bought a new stake in Kestra Medical Technologies during the first quarter worth $431,000. California State Teachers Retirement System boosted its position in Kestra Medical Technologies by 39.2% in the first quarter. California State Teachers Retirement System now owns 27,835 shares of the company’s stock worth $555,000 after purchasing an additional 7,844 shares during the last quarter. Spartan Wealth Advisory Services LLC bought a new position in Kestra Medical Technologies in the 1st quarter valued at $603,000. Corient Private Wealth LP increased its position in shares of Kestra Medical Technologies by 284.2% during the 2nd quarter. Corient Private Wealth LP now owns 60,614 shares of the company’s stock valued at $1,542,000 after purchasing an additional 44,839 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its stake in shares of Kestra Medical Technologies by 47.2% during the 1st quarter. Bank of New York Mellon Corp now owns 70,113 shares of the company’s stock worth $1,397,000 after purchasing an additional 22,471 shares during the period.
About Kestra Medical Technologies
Kestra Medical Technologies, Inc is a medical device company focused on developing and commercializing technologies for patients at risk of sudden cardiac arrest. The company’s primary product is the ASSURE wearable cardioverter defibrillator, a wearable system designed to continuously monitor a patient’s heart rhythm and deliver an electrical shock when a life-threatening arrhythmia is detected.
The ASSURE system is intended to provide temporary protection for patients who may be at elevated risk of sudden cardiac death but are not yet candidates for, or are awaiting, an implantable cardioverter-defibrillator.
Featured Stories
- Five stocks we like better than Kestra Medical Technologies
- Analysts Are Punting Their Calls Into the Next Quarter After Adobe’s Mixed Earnings
- Institutional Money Is Pouring Into These 2 Altcoin ETFs
- The End of Big Tech Buybacks? Only One Hyperscaler Is Still Repurchasing Shares
- 3 Dividend Kings to Buy While They’re Still Beaten Down
Receive News & Ratings for Kestra Medical Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kestra Medical Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
